title: Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
abstract: Liver metastasis is one of the most important prognostic factors in lung cancer patients. However, current therapies are not sufficient. RNA interference provides us a powerful and promising approach for treating human diseases including cancers. Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer. PLK-1 was overexpressed in cell lines and in cancerous tissues from lung cancer patients. PLK-1 siRNA treatment inhibited growth and induced apoptosis in a concentration-dependent manner. To verify in vivo efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted luciferase-labeled A549LUC cells by detecting reduced bioluminescence after an i.v. injection of luciferase GL3 siRNA/atelocollagen. PLK-1 siRNA/atelocollagen was also successfully transfected into cells and inhibited the progression of metastases. This study shows the efficacy of i.v. administration of PLK-1 siRNA/atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer.
authors.affiliation: Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan.
authors.forename: Eri
authors.initials: E
authors.lastname: Kawata
authors.forename: Eishi
authors.initials: E
authors.lastname: Ashihara
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Takenaka
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Sato
authors.forename: Ruriko
authors.initials: R
authors.lastname: Tanaka
authors.forename: Asumi
authors.initials: A
authors.lastname: Yokota
authors.forename: Yuri
authors.initials: Y
authors.lastname: Kamitsuji
authors.forename: Miki
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Junya
authors.initials: J
authors.lastname: Kuroda
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Tanaka
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Taira
authors.initials: T
authors.lastname: Maekawa
mesh_terms: D000368:Aged; D000818:Animals; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology* / Q000648:ultrastructure; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D003094:Collagen; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D000097869:Polo-Like Kinase 1; C059821:atelocollagen